Stephanie Graff, MD
Hematology & Oncology · Kansas City, MONPI 1437187747
Payments from drug & device makers
Across 863 payments — averaging $7213.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.8M
- AstraZeneca$682K
- Genentech, Inc.$652K
- Eli Lilly$582K
- Boehringer Ingelheim$499K
- Daiichi Sankyo Inc.$449K
- plus $554K from 18 others
Across 9 payments — averaging $2549.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$12K
- Eli Lilly$11K
- Novartis Pharma AG$69
What the payments were for
- Consulting fees$66,84164%
- Speaking & faculty fees$18,90018%
- Grants$3500%
- Travel & lodging$14,30314%
- Food & beverage$4,1754%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $2,808,195 |
| AstraZeneca | 32 | $681,573 |
| Genentech, Inc. | 93 | $652,142 |
| Eli Lilly | 46 | $581,541 |
| Boehringer Ingelheim | 8 | $498,786 |
| Daiichi Sankyo Inc. | 400 | $448,615 |
| Seagen Inc. | 35 | $195,864 |
| Roche Products Limited | 21 | $87,965 |
| Merck | 51 | $43,750 |
| Pfizer | 21 | $40,294 |
| Astrazeneca UK Limited | 11 | $38,557 |
| Gilead | 30 | $36,969 |
| Jazz Pharmaceuticals Inc. | 5 | $36,249 |
| Eisai Inc. | 34 | $35,217 |
| E.r. Squibb & Sons, L.L.C. | 2 | $11,067 |
| Lilly USA, LLC | 4 | $10,212 |
| Novartis Pharma AG | 3 | $6,871 |
| Immunomedics, Inc. | 3 | $4,874 |
| Stemline Therapeutics Inc. | 3 | $2,220 |
| Boehringer Ingelheim International GmbH | 5 | $1,668 |
| Genentech USA, Inc. | 5 | $1,348 |
| Taiho Oncology, Inc. | 2 | $779 |
| Incyte Corporation | 19 | $440 |
| Puma Biotechnology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,225,210 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 21 | $331,667 |
| OrserduElacestrant Hcl | 11 | $262,759 |
| Anastrozole | 291 | $4,427 |
| Tamoxifen Citrate | 36 | $577 |
| Letrozole | 20 | $473 |
| Dexamethasone | 42 | $333 |
| Prochlorperazine Maleate | 18 | $234 |
| Ondansetron Hcl | 24 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $40,294 | $331,66721 claims |
| Stemline Therapeutics Inc.Orserdu | $2,220 | $262,75911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Kansas City
- Suman KambhampatiKansas City$4.9M
- Jaswinder SinghKansas City$3.9M
- Shahzad RazaKansas City$1.7M
- Tolga TuncerKansas City$1M
- Whitney HensingKansas City$412K
- Marc RothKansas City$257K
- Furha CossorKansas City$202K
- Frank SlovickKansas City$61K
- Lara KujtanKansas City$28K
- Geoffrey UySaint Louis$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.